Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Phase 2 Completed 60 enrolled National Cancer Institute (NCI)

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase I/II trial to study the effectiveness of pyrazoloacridine plus carboplatin in treating patients who have recurrent glioma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Timeline

Start: 2000-05
Primary completion: 2006-12
Completion: 2007-04

Publications

Results Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs. 2005 Oct;23(5):495-503. doi: 10.1007/s10637-005-2910-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	pyrazoloacridine	Small molecule	400 mg/m2	Intravenous

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Summary

Timeline

Publications

Drugs

Indications